Status:
COMPLETED
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B...
Detailed Description
In China, primary hepatocellular carcinoma (HCC) is mostly a hepatitis B related disease. The liver function of these patients has been damaged, which often limit the execution of major hepatectomy. A...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- age:20-65years old;
- with a clinical diagnosis of primary liver cancer, with HBsAg positive,without any therapy for tumor;
- single lesion with a diameter \>6.5cm,or multiple lesions locating within half liver or adjacent three lobe;
- estimated liver remnant volume ≤40%
- with a liver function of Child-Pugh class A,and ALT≤80IU/l.
- Exclusion criteria:
- reject to attend；
- portal vein trunk has been compressed by tumor;
- diffuse type cancer or with extensive cancer thrombus in main branches of PV,HV,IVC or bile duct;
- with extrahepatic metastasis;
- with obvious portal hypertension (with moderate to severe varix in esophagus and/or gastric fundus, enlarged spleen,WBC\<4×109／L, PLT\<80×109／L)
- with diabetes
- allergy to iodine
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00834158
Start Date
January 1 2009
End Date
November 1 2010
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern Hepatobiliary Surgery Hospital
Shanghai, China, 200438